Extramedullary blast crisis (BC) of chronic myeloid leukemia (CML) has been observed in 7–10% of patients, with or without other manifestation of disease progression [1]. Cerebrospinal involvement as a site of extramedullary BC is rare, but since the advent of imatinib as first-line treatment for CML, there have been several reports describing patients with isolated central nervous system (CNS) involvement [1], [2], [3], [4] and [5] E. Simpson, S.G. O’Brient and J.T. Reilly, Extramedullary blast crisis in CML patients in complete haematological remission treated with imatinib mesylate. Clin Lab Haematol, 28 (2006), pp. 215–216. | View Record in Scopus | | Full Text via CrossRef | Cited By in Scopus (3)[5], because the drug poorly penetrates the blood-brain barrier. Here we report a case of a lymphoid BC, developed under IFN therapy, which reached complete molecular remission with imatinib and presented an isolated relapse of the same disease in CNS after nine years of imatinib therapy
Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib / Breccia, M; Santopietro, M; Cannella, L; Federico, V; Loglisci, G; Serrao, A; Petrucci, L; Salaroli, A; Nanni, M; Propris, Ms; Diverio, D; Alimena, Giuliana. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - STAMPA. - 35:(2011), pp. 91-92. [10.1016/j.leukres.2011.01.026]
Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.
Breccia M;Serrao A;Petrucci L;ALIMENA, Giuliana
2011
Abstract
Extramedullary blast crisis (BC) of chronic myeloid leukemia (CML) has been observed in 7–10% of patients, with or without other manifestation of disease progression [1]. Cerebrospinal involvement as a site of extramedullary BC is rare, but since the advent of imatinib as first-line treatment for CML, there have been several reports describing patients with isolated central nervous system (CNS) involvement [1], [2], [3], [4] and [5] E. Simpson, S.G. O’Brient and J.T. Reilly, Extramedullary blast crisis in CML patients in complete haematological remission treated with imatinib mesylate. Clin Lab Haematol, 28 (2006), pp. 215–216. | View Record in Scopus | | Full Text via CrossRef | Cited By in Scopus (3)[5], because the drug poorly penetrates the blood-brain barrier. Here we report a case of a lymphoid BC, developed under IFN therapy, which reached complete molecular remission with imatinib and presented an isolated relapse of the same disease in CNS after nine years of imatinib therapyI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.